Literature DB >> 18950716

Purification of truncated and mutated Chemotaxis Inhibitory Protein of Staphylococcus aureus--an anti-inflammatory protein.

Erika Gustafsson1, Cecilia Forsberg, Karin Haraldsson, Stina Lindman, Lill Ljung, Christina Furebring.   

Abstract

The Chemotaxis Inhibitory Protein of Staphylococcus aureus (CHIPS) binds and blocks the C5a receptor (C5aR) and formyl-peptide receptor (FPR). This way, CHIPS is a potent inhibitor of the immune cell recruitment associated with inflammation. Truncation of the protein and the introduction of mutations, shifts the expression towards the insoluble fraction of Escherichia coli, whereas the wild-type protein can be solubly expressed. A protocol for expression and tag independent purification of biologically active CHIPS variants has been established to enable further characterization of an improved CHIPS variant, called ADC-1004. The CHIPS variants were purified by washing of E. coli inclusion bodies followed by refolding and gel filtration. New techniques were utilized to optimize the purification process. Expression in inclusion bodies was increased by the use of Ultra Yield flasks and optimal refolding conditions were determined by the use of the iFOLD Refolding System 2. The folding and biological activity of the purified proteins were analyzed by circular dichroism (CD) spectroscopy and flow cytometry, respectively, and compared to solubly produced CHIPS(31-113) and wild-type CHIPS(1-121). We show that the CHIPS variants produced in inclusion bodies can be refolded and purified to achieve equal biological activity as solubly produced CHIPS(31-113) and wild-type CHIPS(1-121). The truncation causes minor structural changes while purification from inclusion bodies or the soluble fraction does not further affect the structure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18950716     DOI: 10.1016/j.pep.2008.09.017

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  6 in total

1.  Tyrosine sulfation in N-terminal domain of human C5a receptor is necessary for binding of chemotaxis inhibitory protein of Staphylococcus aureus.

Authors:  Zhen-jia Liu; Yan-juan Yang; Lei Jiang; Ying-chun Xu; Ai-xia Wang; Guan-hua Du; Jin-ming Gao
Journal:  Acta Pharmacol Sin       Date:  2011-06-27       Impact factor: 6.150

2.  Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model.

Authors:  Jesper van der Pals; Sasha Koul; Patrik Andersson; Matthias Götberg; Joey F A Ubachs; Mikael Kanski; Håkan Arheden; Göran K Olivecrona; Bengt Larsson; David Erlinge
Journal:  BMC Cardiovasc Disord       Date:  2010-09-27       Impact factor: 2.298

Review 3.  Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.

Authors:  Daniel Ricklin
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

4.  Progress and Trends in Complement Therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

5.  Identification of conformational epitopes for human IgG on Chemotaxis inhibitory protein of Staphylococcus aureus.

Authors:  Erika Gustafsson; Pieter-Jan Haas; Björn Walse; Marcel Hijnen; Christina Furebring; Mats Ohlin; Jos A G van Strijp; Kok P M van Kessel
Journal:  BMC Immunol       Date:  2009-03-11       Impact factor: 3.615

6.  A successful strategy for the recovering of active P21, an insoluble recombinant protein of Trypanosoma cruzi.

Authors:  Marlus Alves dos Santos; Francesco Brugnera Teixeira; Heline Hellen Teixeira Moreira; Adele Aud Rodrigues; Fabrício Castro Machado; Tatiana Mordente Clemente; Paula Cristina Brigido; Rebecca Tavares e Silva; Cecílio Purcino; Rafael Gonçalves Barbosa Gomes; Diana Bahia; Renato Arruda Mortara; Claudia Elisabeth Munte; Eduardo Horjales; Claudio Vieira da Silva
Journal:  Sci Rep       Date:  2014-03-04       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.